Delpor is a clinical stage life sciences company that utilizes innovative drug-delivery technologies in order to develop once-yearly therapies for chronic conditions. The Company’s lead product is a 6-12-month formulation of Risperidone (drug/device combination product) for the treatment of schizophrenia. Delpor is also pursuing 6-12 month formulations of other drugs targeting CNS conditions including Neuromuscular Diseases, Neurodegenerative Diseases, Addiction, and other disorders.
Delpor, Inc.的外部链接
150 North Hill Drive
Suite 25
US，CA，Brisbane，94005
Delpor, Inc.转发了
Check out Delpor, Inc. innovative once-Yearly therapies for chronic conditions. They enable drug-sustained release from a small, non-mechanical (passive), subcutaneous implant device. Using a local anesthetic, the device is implanted during a simple, 10-minute, in-office procedure. Learn more at Delpor.com #sbir #sttr #Biotechshowcase
Excellent article about Delpor on Clinical Trials Arena. It outlines our clinical strategy regarding DLP-114 (once-yearly risperidone for schizophrenia maintenance therapy). #schizophrenia #mentalhealth #medicationadherence https://lnkd.in/gpsSdZ6A